Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday
We recently compiled a list of the 10 Firms Buck Market Bloodbath on Monday. In this article, we are going to take a look at ...
Zacks Investment Research on MSN1d
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated ...
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 at Truist Financial
Protagonist Therapeutics (NASDAQ:PTGX – Free Report) had its price objective hoisted by Truist Financial from $60.00 to $76.00 in a research note released on Tuesday morning,Benzinga reports. The firm ...
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
Protagonist Therapeutics’ (PTGX) Buy Rating Reiterated at HC Wainwright
HC Wainwright reissued their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note ...
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success
The joint development project of Protagonist Therapeutics and Johnson & Johnson (NYSE:JNJ) produced Icotrokinra as their ...
Protagonist Therapeutics (PTGX) Gets a Buy from Truist Financial
Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Protagonist Therapeutics (PTGX – Research Report) today. The company’s ...
Protagonist Therapeutics price target raised to $72 from $62 at BMO Capital
BMO Capital raised the firm’s price target on Protagonist Therapeutics (PTGX) to $72 from $62 and keeps an Outperform rating on the shares.
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...
Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra
Protagonist Therapeutics shares were up 28% to $49.25 after the company reported positive topline results from a Phase 2b study of icotrokinra, conducted by partner Johnson & Johnson.